Novusyn Research is an independent editorial desk covering the peptide therapeutics landscape for researchers, clinicians, and the scientific community. We publish news, clinical trial coverage, regulatory tracking, pharmaceutical-company analysis, educational guides, and an A–Z compound directory — all written in neutral, evidence-led language with links to primary sources. We do not sell, distribute, or promote any compound. We do not offer medical advice, diagnose, or recommend treatment.
Our coverage focuses on incretin-based metabolic therapeutics (semaglutide, tirzepatide, retatrutide, orforglipron, CagriSema, survodutide, MariTide), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), longevity research compounds (Epitalon, NAD+, MOTS-C), and the regulatory and pharmaceutical landscape that shapes their development. We follow FDA, EMA, MHRA, and TGA actions; we track late-stage trial enrollment, status, and expected readouts; and we explain the underlying mechanism, methodology, and literature in long-form articles aimed at a scientifically literate audience.
Editorial independence is our operating premise. We accept no payment from sponsors of the trials, regulators, or companies we cover, and no party reviews our coverage before publication. Conflicts of interest are disclosed, corrections are appended transparently, and AI tools used in drafting are reviewed by human editors. The full standards are documented on our Editorial Standards page.